Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing tegoprubart, an anti-CD40L antibody, for transplant and autoimmune-related indications. The company has no approved products and is still in the research, clinical development, and regulatory pathway, so its business is centered on advancing a single lead asset and securing financing to support development.

7.40

7.40

— Eledon Pharmaceuticals, Inc.
%
Lead drug candidate development100% Development of tegoprubart through non-clinical, clinical, and regulatory stages.
Pipeline expansion and in-licensing0% Acquisition or licensing of additional product candidates to broaden the pipeline.
Clinical and manufacturing support activities0% Drug formulation, trial material production, and external manufacturing capabilities.

Eledon does not yet sell approved products, so it does not have commercial customers in the traditional sense...

  • Transplant physicians and centersprimary

    Would use tegoprubart if approved for transplant-related immunosuppression and patient management.

  • Hospitals and specialty care providersprimary

    Would administer or manage treatment in transplant and autoimmune settings.

  • Payers and reimbursement authoritiesprimary

    Would determine coverage, pricing, and reimbursement access for any approved product.

  • Clinical trial sitessecondary

    Enroll patients and execute studies needed to advance tegoprubart through development.

  • Collaborators and license partnerssecondary

    May fund, co-develop, or commercialize assets through strategic arrangements.

Eledon is headquartered in the United States and its development, regulatory, and financing activities are primarily U...

  • •United States is the core operating base and financing market
  • •Clinical development and regulatory work are centered in the U.S.
  • •Europe is relevant for future pricing and reimbursement negotiations
  • •No disclosed country revenue because the company has no product sales
  • •Global competition includes U.S., European, and other biotech peers

Eledon’s strategy is to advance tegoprubart through clinical development, secure regulatory approval, and ultimately...

01
Advance tegoprubart clinical developmentshort-term

The company’s value is concentrated in its lead asset, so clinical progress is essential to any future commercialization.

02
Secure additional capitalshort-term

The company has no product revenue and will need external funding to continue development and operations.

03
Prepare for commercialization and manufacturing scale-upmedium-term

If approval is achieved, the company will need supply, distribution, and market access capabilities.

Eledon is exposed to the typical risks of a clinical-stage biotech: development failure, regulatory delay, and the need...

critical

Clinical development failure of tegoprubart

The company is substantially dependent on one lead asset, and early-stage programs often fail to show sufficient safety or efficacy.

Scope
Lead program concentration
Materiality
high
high

Need for additional financing

The company has no commercial revenue and expects ongoing losses, so it must raise capital to fund operations.

Scope
Dilution and funding risk
Materiality
high
high

Third-party manufacturing and supply disruption

Eledon relies on external manufacturers and has no redundant supply arrangements in place.

Scope
Clinical supply and future commercial supply
Materiality
high
high

Competitive pressure in anti-CD40/CD40L therapies

Larger companies may develop similar therapies faster or with better resources and market access.

Scope
Novartis, Sanofi, UCB, Amgen, BMS, Tonix, Kiniksa
Materiality
high
medium

Pricing and reimbursement constraints

Government control of drug pricing, especially in Europe, can delay or reduce commercial returns.

Scope
Future ex-U.S. commercialization
Materiality
medium
Fair value measurement of warrant liabilities
Can materially affect reported net loss or gain each period
Research and development expense timing
Quarterly operating loss comparability can be uneven
Going concern and liquidity assessment
Important for evaluating capital needs and dilution risk
Stock-based compensation
Impacts R&D and G&A expense levels

LeonaBio, Inc.

LONA · Biological Products, (No Diagnostic Substances)

Cadrenal Therapeutics, Inc.

CVKD · Pharmaceutical Preparations

NEKTAR THERAPEUTICS

NKTR · Pharmaceutical Preparations

Elicio Therapeutics, Inc.

ELTX · Pharmaceutical Preparations

Tectonic Therapeutic, Inc.

TECX · Biological Products, (No Diagnostic Substances)

Viridian Therapeutics, Inc.\DE

VRDN · Pharmaceutical Preparations

: 28/04/2026